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Keywords 
Drug-like Molecule: A molecule with molecular properties that overlap with the majority of 
existing drugs. 
High-throughput Screening: A screening process that utilises robotics and rapid data 
processing to perform millions of assays in a short space of time.  
Molecular Similarity: A measure of the relatedness of two molecules. This would ideally 
quantify the similarity in biological effect but in practice tends to quantify the similarity in 
structure. 
Molecular Diversity: A measure of how well a subset of molecules represents a larger set of 
molecules. A more diverse subset will tend to have a lower molecular similarity between 
molecules. 
Frequent Hitter: A molecule or molecular substructure that hits numerous screening assays on 
different drug targets with a mode of action that is assumed to be non-specific. 
Substructure Filter: A computational filter used to remove molecules containing molecular 
substructures that are considered to give rise to non-specific binding or deleterious 
pharmacodynamic properties. 
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Abbreviations 
 
ADMET: Absorption, distribution, metabolism, elimination and toxicity. 
HTS: High-throughput screening. 
logP: Octanol/water partition coefficient.  
PAINS: Pan assay interference compounds. 
PSA: Polar surface area.REOS: Rapid elimination of swill. 
 
Abstract 
Traditionally a pursuit of large pharmaceutical companies, high-throughput screening assays are 
becoming increasingly common within academic and government laboratories. This shift has 
been instrumental in enabling projects that have not been commercially viable, such as chemical 
probe discovery and screening against high risk targets. Once an assay has been prepared and 
validated, it must be fed with screening compounds. Crafting a successful collection of small 
molecules for screening poses a significant challenge. An optimized collection will minimize 
false positives whilst maximizing hit rates of compounds that are amenable to lead generation 
and optimization. Without due consideration of the relevant protein targets and the downstream 
screening assays, compound filtering and selection can fail to explore the great extent of 
chemical diversity and eschew valuable novelty. Herein, we discuss the different factors to be 
considered and methods that may be employed when assembling a structurally diverse 
compound screening collection. Rational methods for selecting diverse chemical libraries are 
essential for their effective use in high-throughput screens. 
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Introduction 
The earliest efforts in drug discovery focused on crude extracts from natural sources and success 
relied mainly on trial and error. Work in the middle of last century established the concept of a 
molecular disease(1), moving drug discovery in a more rational direction and toward screening 
compounds against a molecular target. Natural products provided the majority of early drugs and 
still remain as an invaluable source of chemicals for screening, along with semi-synthetic 
derivatives(2). In more recent times, the advent of combinatorial chemistry provided a radical 
increase in the number of available screening compounds and this was coupled with high-
throughput screening (HTS) of large chemical libraries(3). Despite many failures amongst the 
successes, HTS remains a widely used method for initiating the process of drug and chemical 
probe discovery(4-9). The concept of a drug-like molecule has existed for many years(10) and 
includes optimized parameters for physicochemical properties as well as functional groups to be 
avoided. This concept has been extended to consider lead-like instead of drug-like 
molecules(11), and this progresses naturally to the identification of hit-like molecules, which are 
geared to provide true positive results in HTS assays and yield a basis for lead generation(12). 
The vastness of chemical space means that there are currently tens of millions of molecules 
available for purchase and screening. Even using harsh filters to remove unwanted compounds, 
there are in the order of a million hit-like molecules available commercially(13-14). However, 
identifying a representative subset of these molecules to screen is a complex task, with multiple 
scientific, financial and logistical considerations. Whilst this review article is unable to 
comprehensively cover the multifold aspects of library design, its aim is to highlight the key 
issues that must be taken into account. This is now important in academic groups and 
government labs as well as in industry(15). Here we review current methods for crafting 
screening compound collections and outline the traps and pitfalls. This will be done in three 
sections: compound sourcing, compound filtering and compound selection. Finally, we highlight 
key challenges to the field and outline future directions. 
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Compound Sourcing 
There are many suppliers of screening compounds, ranging from small chemical suppliers with 
hundreds of compounds to large ones with over a million compounds. Many collections of small 
molecules have been analyzed for drug-like and lead-like properties (13, 16-20) and chemical 
supplier libraries are being increasingly tailored toward these parameters. Details of the main 
screening libraries from six chemical suppliers with varied collections of over 300,000 screening 
compounds are reported in Table 1. At present, all have a high pass rate for commonly employed 
drug-like and lead-like filters. However, compound collections turn over rapidly and should be 
analysed in this way prior to selecting suppliers. Compound prices per milligram vary widely 
dependent on the number of compounds purchased and the sample weight per compound 
required, with significantly lower prices per compound if thousands or tens of thousands are 
purchased. Theoretically, searching the entirety of currently available chemical space 
encompasses the maximum commercially available molecular diversity. In practice, a great 
expanse of available diversity can be sampled by selecting large numbers of compounds from a 
few chemical suppliers with diverse collections. Many chemical suppliers also sell pre-selected 
diverse libraries at reduced cost. These are generally selected by rational means, but the 
compound filters employed may have been too harsh or too lenient, dependent on the nature of 
the screening assay and the target. Furthemore, although the compounds tend to be relatively 
diverse, they are also much more likely to have been tested by other laboratories, as they are for 
sale off-the-shelf. Including novelty in HTS is a vital aspect of drug discovery and many firms 
offer unlisted libraries at higher costs, promising an easier path to intellectual property rights.  
Compound Databases. In addition to compound libraries direct from chemical suppliers, there 
are a number of preassembled online data repositories including ZINC(21) 
(http://zinc.docking.org/), emolecules (http://www.emolecules.com/) and Chemspider 
(http://www.chemspider.com/). The ZINC repository currently has the largest number of 
compounds, including the complete compound libraries of the majority of chemical suppliers. 
The number of molecules in the ZINC set of purchasable compounds currently stands at just 
under 18.7 million. However, chemical suppliers commonly update their libraries every few 
months, which may not be reflected in data repositories such as ZINC. Despite the huge number 
of commercially available compounds, existing chemistry efforts have only probed a small 
proportion of chemical space. The number of synthetically feasible, drug-like molecules is 
estimated to be in excess of 10
60
 (22) and only a small subset of this has been explored. For 
example, data compiled in the Generated Database of Molecules (http://www.dcb-
server.unibe.ch/groups/reymond/gdb/start.html) demonstrates that less than 0.5% of the 
synthetically feasible compounds comprised of up to 11 atoms of C, N, O and F are recorded in 
public databases as having been synthesised(23). Recent studies have also highlighted a large 
number of novel ring systems that are not currently represented in available chemical space(24). 
Many sources of diversity are excluded from existing compound collections and this greatly 
restricts the coverage of chemical space. In particular, the bias against chirality skews 
commercially available compounds toward flat compounds with many aromatic rings(25). This 
in turn may negatively impact on the properties related to absorption, distribution, metabolism, 
elimination and toxicity (ADMET) and increase the risk of attrition during development(26). 
Shelat and Guy have questioned whether libraries of synthetic molecules are suitable for 
addressing novel drug targets and suggest the use of natural products in HTS, particularly for 
phenotypic and high-content screens.  
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Natural Products. The vast majority of commercially available small molecules are obtained 
from synthetic chemistry. Nonetheless, nature is an important source of biologically active 
compounds and natural products have played a key role in drug discovery efforts. It has been 
estimated that as many as 50% of marketed small molecule drugs have been derived from natural 
products(27). However, of the compounds currently approved for marketing each year, natural 
products represent a much lower percentage. Many chemical suppliers sell natural products for 
HTS and some chemical suppliers specialize in natural product chemistry. The natural product 
collections are usually separated from synthetic compounds and can be significantly more 
expensive. However, they can provide unique chemical structures, and may show more drug-like 
ADMET properties(28). Natural products have proven particularly powerful as anti-cancer and 
anti-infective agents(2) and tend to be well suited to phenotypic screening. Recent analysis 
shows that there are many ring systems present in natural products that are not found in 
screening libraries and many have suggested that screening compounds should be further biased 
toward biogenic scaffolds(29-30). However, the advantages of natural products must be balanced 
against their often greater structural complexity that may lead to difficulties in synthesis and 
purification of analogues during lead generation and optimization. There is still great controversy 
over the relative merits of screening natural products or natural product derivatives versus 
screening libraries from combinatorial chemistry or diversity oriented synthesis(31). Both have 
advantages and disadvantages and thus HTS library commonly combine both sources, though 
typically with more synthetic small molecules. Recently, it has been suggested that compounds 
balancing the properties of natural products and synthetic molecules may be optimal(32). 
In summary, there are multiple sources of potential screening compounds and successful libraries 
typically strike a balance between synthetic compounds and natural products. However, whilst 
the growth in commercially available chemical space should always be capitalized upon, many 
compounds are unsuitable for screening in HTS assays and should be filtered out of any quality 
screening collection. 
Compound Filtering 
In order to obtain commercially available hit-like compounds, computational filters are 
commonly used to remove compounds with undesirable properties. Ideal drug-like and lead-like 
molecules have differing properties and these differ again from hit-like molecules. In general, the 
physicochemical properties of a lead-like molecule can be improved during lead optimization 
toward a drug-like molecule by tailoring the lipophilicity. Similarly, the binding affinity of a hit-
like molecule can be improved during the process of hit explosion to yield a lead-like molecule. 
However, hit-like molecules must be large and lipophilic enough to gain sufficient binding 
affinity that they can be identified in a screening assay, but not so large that they have a very 
small probability of binding. Larger and more complex molecules have a lower probability of 
exhibiting perfect shape and electrostatic complementarity with any given target and this 
suggests that smaller and less complex molecules will more commonly provide starting points 
for drug development(33). An ideal hit molecule should also be amenable to chemical 
elaboration, show reasonable levels of cell permeability and have a range of commercially 
available analogues, some of which have also been tested in the same assay. 
Computational Filters. There are numerous computational filters used to mark compounds that 
may have problems due to assay interference or downstream ADMET properties. The most 
commonly used of these are physicochemical property filters that specifically attempt to remove 
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compounds that may lead to low levels of drug absorption and distribution. An exception that is 
ignored by these filters is compounds that are substrates for drug transporters, which recent 
works suggests may be a significant proportion of molecules(34). In addition to Lipinski’s well 
known rule of five(35), Ghose filters(36) and Veber filters(37) are commonly employed to filter 
compounds. Noteworthy analysis has also been performed by Walters(38), Oprea(39), Egan(40), 
Lee(41), Baurin(13) and Martin(42). The key properties that determine drug absorption and 
distribution for an oral drug are the lipophilicity measures of the octanol/water partition 
coefficient (logP) and surface area of the polar atoms in the molecule (PSA)(43-45). Analysis of 
trends in launched drugs has highlighted a significant increase in molecular weight in the last 
fifty years, but a negligible increase in logP values(46). This is not surprising, as drugs with 
increased logP tend to be more promiscuous binders and can thus be expected to have a higher 
attrition rate in later development(47). However, studying the most recent trends in molecules 
being synthesized in leading drug discovery companies suggests an increase in both molecular 
weight and logP(46). This has been attributed to the fact that more lipophilic drugs have the 
potential to be more efficacious, as they tend to have increased binding affinity. It has been 
suggested that this may adversely affect drug attrition rates in the future due to an increased 
likelihood of toxicity(48). However, as discussed, larger and more complex molecules have a 
lower probability of exhibiting perfect shape and electrostatic complementarity with any given 
target and they are thus expected to show greater specificity(33). This predicted increase in 
promiscuity due to increased lipophilicity may thus be ameliorated by increased complexity. 
Despite the noted increase in molecular weight, there is great pressure during the development 
process to lower the molecular weight, likely because larger molecules show reduced passive 
absorption across cell membranes, increased number of toxic pharmacophores or rapidly 
metabolized moieties(49). One caveat when filtering on lipophilicity or solubility is to note 
whether you are using experimental values or predicted values. Solubility predictions based on 
clogP values or PSA can be accurate in some circumstances, but are inaccurate in others and tend 
to perform particularly badly for charged compounds(50). Charged compounds may be better 
represented by the octanol/water distribution coefficient logD, which takes into account the 
different protonation states. It is vital to carefully consider whether compounds should be 
excluded based on predicted insolubility, when such predictions can be inaccurate. 
One other significant method for marking ADMET risks are the Rapid Elimination of Swill(51) 
(REOS) filters. As well as physicochemical properties, REOS filters remove molecules 
containing certain functional groups, as described by SMILES or SMARTS patterns(52). Some 
of these are shown in Figure 1. REOS filters flag compounds containing functional groups that 
may lead to false positives due to reactivity or assay interference, which have long been noted as 
a problem in HTS efforts(53). They also remove compounds containing functional groups known 
to be risks for ADMET. However, it is important to note that many known drug molecules fail 
the common physicochemical and substructure filters. The Drugbank(54) 
(http://www.drugbank.ca/) contains structural data for over 1,350 FDA approved small molecule 
drugs and nearly 5000 experimental drug entries. Analysis of the Drugbank experimental drugs 
is shown in Table 1 and reveals that only 71.4% pass all of the Lipinski filters and only 51.7% 
pass all of the REOS substructure filters. This data highlights that compound filtering is used to 
reduce risk, but will also eliminate useful molecules from further consideration. More recently, a 
Herculean analysis of compounds hitting multiple orthogonal HTS assays has lead to the 
identification of pan assay interference compounds (PAINS)(55). As increasing amounts of assay 
data from different HTS efforts around the world is becoming publically available, a clearer 
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picture of compounds and functional groups that tend to yield false positives is developing(56). 
This development is vital, as frequent hitters are likely to be over represented in compounds from 
chemical vendors due to an increased likelihood that they will be ordered as analogues of 
apparent hits. Research has also specifically highlighted substructures that alert when a 
compound may be a DNA-reactive genotoxin(57). Whilst this may be acceptable in a screening 
hit, it would almost certainly have to be removed in the hit to lead process. 
Physicochemical Property Filters. The majority of physicochemical property filters are simple to 
understand. Eight drug-like filters and one lead-like filter are described in Table 2. There is 
general agreement, although the exact properties vary slightly. Any of these rules can be used, 
alone or in conjunction, to filter a set of compounds and it is worth noting that many of the 
properties are highly correlated, such as logP and PSA. However, due consideration must be 
given to the details of the screening assay and the nature of the target as this affects the desired 
physicochemical properties of the screening compounds. For example, a fragment with a 
molecular weight of 200 may be too small to show measurable binding in typical HTS assays or 
compete with high-affinity ligands. However, if the assay is tailored to identify smaller 
molecules, fragment based methods have been shown to be very useful, with higher ligand 
efficiencies(58) and a greater potential for chemical elaboration and linking(59). Compound 
filters for fragments are completely different to filters for traditional small molecules. Phenotypic 
screens also place a different pressure on the screening library, with considerably more emphasis 
on cell permeability at the initial stage. As well as the importance of the assay format, the 
composition of an ideal screening library also varies with the protein target. Many existing 
screening libraries and are tailored toward screening against a narrow range of targets such as 
kinases and GPCRs(60). A screening library tailored toward screening against protein-protein 
interactions would have a very different profile. Recent analysis collected in the TIMBAL 
database(24) suggests that inhibitors of protein-protein interactions have higher molecular 
weights and lipophilicity than inhibitors of buried binding sites, as well as a greater number of 
hydrogen bond donors, hydrogen bond acceptors and rotatable bonds. Whilst the general 
applicability of this approach to generating approved drugs remains to be seen, it is an important 
consideration. As well as traditional physicochemical property filters, there are now a number of 
flags for more complex properties(61). Increasing evidence shows that small molecules may 
cause non-specific protein aggregation(62) and thus lead to false positives in some assays. 
Experimental work has shown that a significant number of compounds may act in this way and 
potential risks can be identified and removed from consideration(63). There are also 
experimental methods to identify compound that are reactive, such as ALARM NMR(64), and 
also for compounds containing fluorophores(65). However, whilst the latter is of great 
importance for fluorometric assays, it is of little or no importance in other assays. Experimental 
studies such as PAINS have identified molecular scaffolds that form the basis for promiscuous 
inhibitors and thus yield false positives in many screening assays(55, 66). Defining the 
mechanism underlying the promiscuous inhibition of these PAINS compounds will no doubt 
provide significant but interesting challenges in the next decade. In addition there are now 
methods for predicting compounds that disrupt particular screening assays(67), but these 
methods are approximate and should be used with this understanding. 
Substructure Filters. Many filters simply remove compounds with specific functional groups that 
are known to interfere with HTS assays or cause problems later in drug development. The 
importance of removing these functional groups has been discussed in numerous papers(38, 53). 
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The majority of screening libraries contain very few if any of the most troublesome compounds 
such as aldehydes, epoxides or α-halo ketones. The prevalence of these three groups in the six 
supplier databases is on average 0.3%, 0.01% and 0.04% respectively. However, many still 
contain potential risks such as isolated alkenes (12.3%), αβ-unsaturated carbonyls (8.5%) or nitro 
groups (7.6%). The prevalence of the more common functional groups can be seen in Table 3. 
Each of these substructures is a potential liability for the reasons described in Box 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
However, many of these functional groups do appear in certified drug molecules(68), as shown 
in Table 3, and many show no activity in HTS assays(69). When eliminating functional groups 
due to any ADMET risk, the nature of the functional group should be considered. It may be 
easier to replace a potentially risky side-group at the hit-to-lead stage than a potentially risky 
core group. For example, a nitroaromatic side-group can be replaced with another similar side-
group such as a trifluoromethanesulfonyl side-group to retain or increase binding affinity without 
disrupting the structure of the molecule(70). The same is not true for a 2-aminothiazole core 
group, as its shape and hydrogen bonding characteristics are more difficult to mimic without 
disrupting the structure of the molecule. Despite this, scaffold hopping can be achieved and is 
increasingly common(71). When eliminating functional groups due to the risk of cytotoxicity, it 
is important to consider the target, as some therapies (for cancer in particular) are damaging to 
cells. For example, 2-aminothiazoles may lead to cytotoxicity but they form the basis of a 
number of potent CDK inhibitors for cancer therapy(72). Functional groups implicated in organ 
toxicity may also be acceptable in chemical probe discovery. 
Filtering Tools. There are a number of software packages used to predict chemical properties 
and/or filter screening compounds. This includes Accelrys’ Pipeline Pilot(73), MOE’s 
sdfilter(74), Schrodinger’s qikprop(75) and Openeye’s filter(76), which is freely available to 
Box 1. Screening Liabilities 
 1,2 dicarbonyls – Metabolically unstable/Potential toxicity due to mutagenicity. 
 1,2 dimethoxys – Prone to oxidation yielding reactive quinones. 
 1,4 dimethoxys – Very prone to oxidation yielding reactive quinones. 
 αβ-Unsaturated Carbonyls – Prone to reactivity by acting as a Michael acceptor. 
 Acetals – Metabolically unstable due to acetal hydrolysis. 
 Acylhydrazides – Metabolically unstable due to acyl hydrolysis. 
 Aliphatic Ketones – Metabolically unstable due to nucleophilic attack. 
 Alkenes – Metabolically unstable due to epoxidation. 
 Aminothiazoles – Potential toxicity. 
 Anthracene/Phenanthrene-likes – Known DNA intercalation. 
 Nitro Groups – Prone to reduction yielding reactive species/Potential 
hepatocarcinogens. 
 Methylenedioxys – Metabolically unstable due to acetal hydrolysis/Prone to oxidation 
yielding reactive quinones. 
 Thioureas – Metabolically unstable due to flavin oxidation/Potential non-specific 
protein binding. 
 Unflanked Pyridyls – Potential interference with cytochrome P450s due to metal ion 
coordination. 
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academics. Once the filtering process is complete, it is important to inspect a subset of the 
resulting structures. No matter how sophisticated the filtering criteria and algorithms, a scientist 
should always ensure that the remaining compounds meet their requirements. Despite the 
importance of filtering compounds to prevent screening potentially problematic compounds, it is 
common to screen a small proportion of "wildcards" that do not pass all of the filters. As seen in 
Tables 1 and 2, many drug molecules do not pass the drug-like or lead-like filters and contain 
significant proportions of functional groups that are commonly removed by HTS filters. For 
example, the REOS rule to exclude compounds with more than four joined rings, removes all 
steroids and nearly 10% of the Drugbank experimental drugs. It is important to realise that the 
process of compound filtering is about minimising risk and downstream expenditure rather than 
maximising hit-rate. For example, reactive groups may present the risk of false positives, but 
work has shown that this is not always the case(69). In some cases, reactive groups can act as 
covalent inhibitors, inactivating the target by binding irreversibly, and thus provide an advantage 
over non-covalent inhibitors. However, this activity may be difficult to extract from HTS data as 
it can be hard to discriminate from unwanted reactivity. Potentially reactive compounds should 
remain, at most, a small percentage of any screening library, unless there is a clear plan to extract 
useful data on covalent inhibition from the screening assay. 
In summary, it may be necessary to rethink the process of designing libraries for screening 
against the more diverse range of targets now being considered. Research at Harvard(77), the 
NIH(6, 78), and the DDU in Dundee(9) amongst others has shown that HTS is feasible in a non-
industrial center and can be vital in developing treatments for neglected diseases. Whilst such 
drug development projects must also select screening compounds with care, many of the 
functional group and physicochemical property filters are unsuitable for screening efforts aimed 
at development of chemical probes. Compounds causing assay interference or low solubility 
should be avoided, but compounds causing liver toxicity or poor oral absorption may be 
acceptable. Recent analysis suggests that the nature of screening hits is shifting to larger and 
more lipophilic molecules as a result of the increased use of in vitro assays over in vivo 
assays(79). This is expected to shift or widen the nature of screening libraries. However, the 
exact nature of the assay and the target must be considered when selecting compound exclusions 
as, for a diversity library aiming to span multiple assays and targets, it may not be appropriate to 
remove all potential risks. A balance must be reached between filtering out all compounds that 
are a risk in any drug development program and only filtering compounds that are a risk in all 
programs. There is now a critical mass of published data highlighting risks for compound 
interference and this can easily be applied to hits post screening, along with experimental 
methods to detect false positives such as dose-response plotting. This should ensure that 
screening libraries take advantage of the enormous diversity in chemical space, whilst assessing 
risk appropriately. With respect to chemical diversity, chemical suppliers will only provide chiral 
compounds if there is a market for them and thus filtering out chiral compounds from screening 
libraries will drive the purchasable chemical space further in this direction and away from 
biogenic chemical space. 
Compound Selection 
Aggressive filtering may remove up to 50% of compounds from consideration, but huge numbers 
of commercially available compounds still remain. The main aim of compound selection is to 
pick a subset of these compounds for testing. In general, it is wasteful to test many compounds 
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with similar structures in frontline assays, at the expense of more diverse compounds. Analysis 
has shown that if a compound is biologically active, a molecule with very high similarity will 
have a similar biologically activity and thus testing the second molecule in the frontline assay is 
unlikely to be worthwhile(80-81). It is thus common to select a structurally diverse subset of 
compounds that represents the chemical space being considered. However, chemical space grows 
very rapidly with molecular size and, in 200 years of chemical synthesis, we have covered only a 
tiny fraction of chemical space up to a molecular weight of 500. The biggest screening libraries, 
which are of the order of tens of millions of molecules, can never hope to cover this space. 
Approaching compound selection in a sensible manner is thus very important(82). 
Measuring Chemical Diversity. Molecular similarity is a key prerequisite in assessing molecular 
diversity(83). There are many different techniques to measure whether two compounds are 
similar(81, 84) but none of them are entirely satisfactory. From a pharmaceutical perspective, the 
ideal metric would predict that two compounds are similar if they elicit the same biological 
effect by hitting the same biological target and binding in the same pose. Unfortunately such a 
metric does not exist. Currently used metrics predict that two compounds are similar if they have 
similar chemical connectivity or similar shape and electrostatic form. One important issue in 
assessing chemical similarity is that a compound can be very different in its various 
conformations, tautomers and protonation states. Two compounds that are calculated to be 
similar in specific tautomeric states may be calculated to be different in other states. However, 
there are numerous computational methods for the enumeration of protonation and tautomeric 
states. This includes Schrodinger's Ligprep(85), the Openeye toolkit(76), CCG's MOE(74), 
Tripos Sybyl(86) and Accelrys' Discovery Studio(73). Three of the most common methods for 
predicting similarity are fingerprint(87), shape-based(88) and pharmacophore(71) methods. 
These methods are commonly used in virtual screening when a known active compound has been 
identified. Fingerprint methods are relatively simple and usually two-dimensional. Each 
molecule is assessed for a number of atom and bond connectivities. Each of these connected 
units is termed a bit/key and the combination of bits/keys that are present in a given molecule is 
its fingerprint. Two molecules with similar fingerprints have similar atoms in similar bonding 
environments and are likely to bind in similar ways to a protein target. There are a number of 
fingerprinting techniques as well as a number of atom-typing schemes and close reading of the 
current literature is recommended before selecting a method, as this is still a rapidly developing 
field(89). Recent analysis has shown that atom-type based radial fingerprints perform well(90) 
but other work suggests that fingerprints based on physicochemical properties or 
pharmacophores may perform better(91). Different fingerprinting methods can yield very 
different similarities and thus an exact comparison with literature is not always appropriate. 
There are also a number of similarity/difference metrics(92) and, whilst the Tanimoto metric is 
most commonly used, close reading of the current literature is again recommended. The 
molecules in Figure 2 were analyzed using radial fingerprints based on daylight atom types using 
Schrodinger’s Canvas software and Tanimoto similarity scores were then generated. As can be 
seen, molecule with a high similarity such as A and B are very similar and would likely give 
similar assay results, whereas molecule A and D are significantly different and should ideally 
both be tested in a frontline assay. Shape based methods compare molecules by analyzing 
whether they have the same shape and electronic form. This is implemented in Openeye's ROCS 
and EON software(76), which is widely used and is freely available to non-commercial groups 
working toward public disclosure(93). Pharmacophore methods have the obvious advantage of 
including the three dimensional geometry of the molecules. As noted, chemical similarity is a 
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very important concept in assessing chemical diversity. Whilst three dimensional methods have 
the potential to provide a much more accurate model of molecular similarity, there is great 
difficulty in applying them when the bioactive conformation is unknown, as is the case in 
diversity analysis. Thus, two dimensional methods such as fingerprinting remain the tool of 
choice at present. 
Rational Selection. Once a set of compounds has been analyzed on the basis of similarity it is 
possible to select a diverse set of compounds. In some cases it is possible to consider the average 
similarity between compounds and optimise this as an objective function. However, this requires 
generation of an N by N similarity matrix, which may become prohibitively large as N 
increases(94). Heuristic clustering methods are thus more commonly used(94). Such methods 
include k-means clustering(95), sphere exclusion(96), directed sphere exclusion(97) and 
maxmin(98). The aim of such methods is that, for each selected molecule, no similar molecules 
are then selected. This is illustrated using a two dimensional representation for a simple sphere 
exclusion method in Figure 3. The centroid molecules R, B, G and Y represent all the molecules 
within a similarity of greater than 0.2. Iterative selection in this chemical space will finally 
encompass all molecules. A secondary aim of compound selection is to pick clusters of two or 
more structurally similar compounds in each cluster, such that the initial assay results 
immediately provide some QSAR data to inform decision-making. In many cases the aim of 
compound selection is to augment an existing compound collection. In this case, the existing 
compound structures can be used as an input to the diverse selection algorithm. This can be used 
to select new compounds that “fill the gaps” in chemical space. Despite this usefulness of 
diversity selection methods, the use of virtual screening methods should always be considered in 
a resource constrained environment, with sufficient knowledge of the protein target and its 
structure. Both molecular docking(99) and pharmacophore analysis(100) can improve hit rates in 
HTS assays and are commonly used.  
In summary, the process of selecting a representative subset of compounds from a large 
collection relies heavily on the ill-defined concept of molecular similarity. However, the concept 
is vital as it allows lead molecules to be identified at reduced cost and effort through hit 
identification and explosion. 
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Conclusions 
Shrewd selection of screening compounds is one of the most vital enabling steps in the drug 
development process. There are no strict rules, only rules of thumb. No compound filters are 
globally applicable and no diversity metrics or selection methods can be proven as optimal. 
However, misapplication of filtering can reduce chemical diversity within a project and preclude 
many novel discoveries. Conversely, careful filtering reduces the risk of false positives and 
downstream ADMET failures, whilst sensible compound selection can yield libraries that cover 
larger regions of chemical space and increase true positive hit rates. ADMET concerns may not 
be as important for chemical probes developed in academic groups, but solubility, cell 
permeability and potential chemical reactivity are all still important considerations and chemical 
diversity is still highly desirable. There are numerous sources of compound interference, which 
plague HTS assays. However, recent large-scale analyses have identified molecular scaffolds 
that appear as frequent hitters in numerous assays. The resultant data is very useful and should be 
incorporated either into library filtering or triaging of assay data. However, if every group used 
the same filters then every group would test similar compounds and many useful molecules 
could be missed. Large screening libraries in industry include a substantial fraction of 
commercially available compounds. Thus, if an academic group sources from commercial 
vendors and uses traditional industry filters then they will develop smaller relatives of the big 
industrial libraries with little or no chemical novelty. It may thus be advisable for academics to 
consider synthesizing or purchasing molecules in untapped regions of chemical space, 
particularly embodying multiple stereogenic centers, to maximise chemical diversity and 
increase the number of unique chemical entities tested. Diversity should also be maximised by 
considering natural products and biogenic scaffolds, which may show improved ADMET 
properties. At present, commercially available chemical space is heavily skewed toward flat 
compounds with many aromatic rings. Whilst this makes synthesis more tractable, it excludes 
many sources of chemical diversity and shifts screening libraries away from biogenic scaffolds 
and toward pharmacological risks. These risks have been recently quantified and the results are 
compelling(26). This problem will only be remedied by customers changing their practices to 
incentivise chemical suppliers. 
 A screening library must have the correct balance of molecular weight and logP, tailored to the 
constraints of the assay. Once a true positive hit has been identified, increasing size and 
complexity in tandem with lipophilicity is expected to increase both affinity and specificity. It is 
important to note that the ideal range of chemical and physicochemical properties of an HTS 
library differs when considering different assay platforms or protein targets. An optimal 
screening library for a fragment-based screen or targetting a protein-protein interaction will thus 
be different from a traditional kinase set and should be carefully designed. Due to the economies 
of scale with respect to purchasing a screening library, cost sharing between academic and 
government labs can increase the scope of screening efforts. Some companies may be willing to 
share portions of their screening libraries, in return for IP rights, on projects focused on 
commercially viable, validated targets. With respect to compound selection, there are numerous 
existing methods for measuring chemical similarity and selecting diverse sets of compounds, but 
no ideal metric can exist. Whilst current work has highlighted the best applications of 
fingerprinting, shape-based and pharmacophore methods, these are all evolving fields and no 
technique can be proven superior in all cases. However, compound selection through analysis of 
molecular similarity reduces the size and cost of screening libraries whilst retaining diversity. 
14 
 
One question of great importance that has not been addressed in great detail is how many 
compounds need to be tested to ensure a sufficient coverage of chemical space(101). This 
question can be considered by considering the number of lead series desired, the false positive 
rate, the number of molecules assayed per cluster and the hit rate of the primary screen. Such an 
analysis predicts that on average one lead series can be developed from testing approximately 
350,000 diverse compounds in a typical HTS screen(102). This number applies only to leads 
successfully developed into marketed drugs and is thus not appropriate when considering 
chemical probe discovery. However, it is commonly accepted that some targets are more 
druggable than others such that this value can vary greatly and that some screens will yield no 
successful lead series. Due to the importance of HTS in the development of new drugs and 
chemical probes, high-quality screening libraries are a key asset of any research group and there 
are many factors to be weighed. However, each library will be unique and should be suited to the 
particular needs of the screening group. With the rapid increase in the number of purchasable 
molecules, the almost limitless volume of chemical space and the proliferation of HTS groups, 
rational selection of diverse hit-like compounds seems likely to continue as a lynchpin of drug 
development.  
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Tables 
Table 1 - Details of the screening libraries for six chemical suppliers, the ZINC database of 
purchasable molecules and the Drugbank database of experimental drugs. All physicochemical 
properties were generated with Qikprop and filtering was performed with Canvas.The compound 
collection refers to the subset of molecules that was analyzed from each source. 
Compound 
Source 
Compound 
Collection 
URL 
Number Of 
Compounds 
% 
Lipinski 
Passes 
% 
REOS 
Passes 
Asinex 
Gold and Platinum 
Collections 
http://www.asinex.com 364407 79.6 73.0 
Chembridge 
Express Pick 
Library 
http://www.chembridge.com 442051 84.0 66.6 
ChemDiv 
Discovery 
Chemistry 
http://www.chemdiv.com 789603 73.8 72.1 
Enamine HTS Collection http://www.enamine.net 1116406 90.7 79.6 
Life 
Chemicals 
Stock http://www.lifechemicals.com 327211 84.9 76.6 
Vitas M Labs HTS Stock http://www.vitasmlab.com 476184 75.1 65.8 
Drugbank All Drugs http://www.drugbank.ca 4886 71.4 51.7 
Zinc 
Purchasable 
Compounds 
http://zinc.docking.org 18671085 87.2 73.1 
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Table 2 - Details of physicochemical property filters to mark drug-like and lead-like 
compounds for screening libraries. LTE stands for less than or equal to.  
 MW 
PSA 
(Å
2
) 
HBA HBD logP 
Rotatable 
Bonds 
# 
Atoms 
Charge 
Lipinski 
(1997) 
LTE 500  0 to 10 0 to 5 LTE 5.0    
Ghose 
(1999) 
160 to 480    -0.4 to +5.6  20 to 70  
Oprea 
Drug-Like 
(2000) 
  2 to 9 0 to 2  2 to 8   
Egan 
(2000) 
 LTE 130   -1.0 to +5.8    
Walters 
(2000) 
200 to 500 LTE 120 0 to 10 0 to 5  0 to 8 20 to 70 -2 to +2 
Oprea 
Lead-Like 
(2001) 
LTE 450  0 to 8 0 to 5 -3.5 to +4.5    
Veber 
(2002) 
 LTE 140    0 to 10   
REOS 
(2002) 
200 to 500  0 to 10 0 to 5 -5.0 to +5.0 0 to 8  -2 to +2 
Martin 
(2005) 
 LTE 150       
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Table 3 – Percentage of compounds failing common drug-like filters for unfavourable 
physiochemical properties and unwanted substructures for the six combined chemical supplier 
libraries, the ZINC database of purchasable molecules and the Drugbank database of 
experimental drugs. All physicochemical properties were generated with Qikprop and filtering 
was performed with Canvas. 
 
 Combined Suppliers Drugbank ZINC 
clogP > 5 15.8 7.0 10.7 
HBA > 10 3.8 23.0 6.7 
HBD > 5 0.0 13.1 0.1 
MW > 500 4.9 13.3 1.7 
PSA > 150 1.8 22.0 3.3 
Rotatable Bonds > 10 1.5 20.3 2.5 
Isolated Alkene 9.1 12.3 8.7 
αβ-Unsaturated Carbonyl 8.5 8.5 6.9 
1,2-Dimethoxy 7.6 6.0 7.6 
Nitro 7.4 6.6 6.5 
Acylhydrazide 4.0 4.6 4.1 
Aminothiazole 4.0 4.8 3.1 
Thiourea 3.3 4.3 1.6 
Anthracene/Phenanthrene-like 3.1 5.9 1.2 
Unflanked Pyridyl 3.1 5.9 2.5 
Acetal 2.7 13.0 2.0 
Methylene-Dioxy 2.3 4.6 1.5 
Aliphatic Ketone 2.1 10.6 2.0 
1,2 dicarbonyl 1.6 5.6 1.0 
1,4-dimethoxy 1.5 4.5 1.6 
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Figure Legends 
 
Figure 1 - Chemical structures used in compound filtering. Chemical structures of functional 
groups commonly used to remove compounds from consideration in HTS assays. The functional 
group name and SMILES/SMARTS string used in the filter are reported. 
Figure 2 – Example of similarity between compounds. Four compounds and the Tanimoto 
similarity between them. The compounds were assigned radial fingerprints using Schrodinger's 
Canvas software at 64-bit precision using daylight invariant atom types.  
Figure 3 – Clustering of compounds in chemical space. A two dimensional representation of 
chemical space being partitioned into clusters of similar compounds using a simple sphere 
exclusion method. 
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